Amyris (NASDAQ:AMRS) Shares Gap Up to $4.53

Amyris Inc (NASDAQ:AMRS)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $4.43, but opened at $4.53. Amyris shares last traded at $4.53, with a volume of 2,847,900 shares.

Several equities research analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Amyris from a “hold” rating to a “sell” rating in a research note on Friday, June 12th. Oppenheimer began coverage on Amyris in a research report on Friday, June 5th. They issued a “buy” rating and a $9.00 target price for the company. Finally, ValuEngine raised Amyris from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $7.83.

The company’s fifty day simple moving average is $3.99 and its two-hundred day simple moving average is $3.15.

Amyris (NASDAQ:AMRS) last posted its earnings results on Friday, May 8th. The biotechnology company reported ($0.56) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.37). The company had revenue of $29.13 million for the quarter, compared to the consensus estimate of $34.51 million. As a group, equities research analysts forecast that Amyris Inc will post -0.75 earnings per share for the current fiscal year.

In related news, Director Frank Kung bought 3,689,225 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were bought at an average price of $3.00 per share, for a total transaction of $11,067,675.00. Following the completion of the acquisition, the director now directly owns 2,932 shares of the company’s stock, valued at $8,796. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 47.40% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. California Public Employees Retirement System lifted its position in shares of Amyris by 238.1% during the fourth quarter. California Public Employees Retirement System now owns 41,263 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 29,058 shares in the last quarter. Rhumbline Advisers increased its stake in Amyris by 27.3% in the 4th quarter. Rhumbline Advisers now owns 69,054 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 14,796 shares during the last quarter. Swiss National Bank lifted its position in shares of Amyris by 7.1% during the 4th quarter. Swiss National Bank now owns 98,600 shares of the biotechnology company’s stock worth $305,000 after buying an additional 6,500 shares in the last quarter. State Street Corp boosted its stake in shares of Amyris by 31.5% in the 4th quarter. State Street Corp now owns 880,717 shares of the biotechnology company’s stock worth $2,721,000 after buying an additional 210,796 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Amyris by 52.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 141,542 shares of the biotechnology company’s stock valued at $438,000 after acquiring an additional 48,993 shares in the last quarter. Institutional investors own 29.16% of the company’s stock.

About Amyris (NASDAQ:AMRS)

Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.

Featured Article: Moving Average Convergence Divergence (MACD)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.